Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.

Mona HamdyIman A ShaheenMohamed KhallafYasmeen M M Selim

Published in: Pediatric blood & cancer (2024)

The analysis of Thr325Ile polymorphisms combined with plasma TAFI levels suggests that the analyzed SNP could influence plasma TAFL levels and SCD disease severity and hospitalization rates, which could be predictors for complex disease.

Keyphrases

sickle cell disease
end stage renal disease
genome wide
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
gene expression
photodynamic therapy
patient reported outcomes